Kandzari S J, Riley R S, Belis J A, Jain P R
Prostate. 1986;9(4):319-26. doi: 10.1002/pros.2990090403.
One hundred twenty patients with adenocarcinoma of the prostate were treated with 125I irradiation to the prostate and pelvic lymphadenectomy. Clinical stages were A-2 (13 pts), B-1 (34 pts), B-2 (49 pts), and C-1 (24 pts). The tumors were well differentiated in 44%, moderately differentiated in 39% and poorly differentiated in 17%. Nineteen of 22 patients with positive lymph nodes had either moderately or poorly differentiated tumors. A total radiation dosage between 15,000 and 24,000 rads per year were given to all patients. Seventy-six patients had been rebiopsied at 1 year, and 26 were positive for malignancy (34%). Thirty-eight patients had rebiopsy at 2 years, and 16 were positive (42%). Forty-four percent of the postradiation biopsies were of a different histologic grade from the primary lesion. Radiation injury was identified in 95% of the posttreatment biopsies and were moderate or severe in 71%. One hundred one patients are living from 1 to 9 years. Eight patients have died of metastatic carcinoma, and 11 have died of cardiovascular problems.
120例前列腺腺癌患者接受了前列腺¹²⁵I照射及盆腔淋巴结清扫术。临床分期为A - 2期（13例）、B - 1期（34例）、B - 2期（49例）和C - 1期（24例）。肿瘤高分化占44%，中分化占39%，低分化占17%。22例淋巴结阳性患者中有19例为中分化或低分化肿瘤。所有患者每年接受的总辐射剂量在15000至24000拉德之间。76例患者在1年时接受了再次活检，其中26例恶性结果呈阳性（34%）。38例患者在2年时接受了再次活检，16例呈阳性（42%）。44%的放疗后活检组织学分级与原发灶不同。95%的治疗后活检发现有放射损伤，其中71%为中度或重度损伤。101例患者存活1至9年。8例患者死于转移性癌，11例患者死于心血管问题。
